Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

Clinical trial NCT06359379 · TERMINATED

Trial details

NCT number: NCT06359379
Sponsor: Shuttle Pharmaceuticals, Inc.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Glioblastoma, IDH-wildtype

Start date: 2024-09-02
Primary completion: 2025-12-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.